Amicus Therapeutics, Inc.
FOLD
Κατάταξη σε μετοχές
#3694
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Τιμή μετοχής
$14.49
Τελευταίος συγχρονισμός: 2026-04-27
Κεφαλαιοποίηση
$4.55B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
71.68%
Χώρα
US
Εμπόριο Amicus Therapeutics, Inc. (FOLD)
Κατηγορία
Healthcare
Δείκτης P/S για Amicus Therapeutics, Inc. (FOLD)
Δείκτης P/S στις October 2026 TTM: 8.94
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Amicus Therapeutics, Inc., ο τρέχων δείκτης P/S (TTM) είναι 8.94. Στο τέλος του 2023, ο δείκτης ήταν 10.49.
Ιστορικό P/S για την Amicus Therapeutics, Inc. από 2003 έως 2026
Δείκτης P/S στο τέλος κάθε έτους
| Έτος | P/S Ratio | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 8.94 | 64.63% |
| 2024 | 5.43 | -48.25% |
| 2023 | 10.49 | -2.17% |
| 2022 | 10.72 | 4.47% |
| 2021 | 10.26 | -55.21% |
| 2020 | 22.91 | 78.30% |
| 2019 | 12.85 | -34.13% |
| 2018 | 19.51 | -67.36% |
| 2017 | 59.76 | -55.65% |
| 2016 | 134.73 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | 506.03 | 52.41% |
| 2013 | 332.02 | 4,905.76% |
| 2012 | 6.63 | 19.55% |
| 2011 | 5.55 | -96.08% |
| 2010 | 141.38 | 10,030.50% |
| 2009 | 1.40 | -88.36% |
| 2008 | 11.99 | -84.96% |
| 2007 | 79.76 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
Δείκτης P/S για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | P/S Ratio | Διαφορά P/S Ratio | Χώρα |
|---|---|---|---|
| 10.02 | 12.11% |
US
|
|
| 40.55 | 353.61% |
US
|
|
| 3.96 | -55.69% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 13.50% |
NL
|
